Key Details
Annual ROE
-184.13%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Mar 10, 2023Recent annual earnings:
Mar 10, 2023Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
May 22, 2019Analyst ratings
Recent major analysts updates
No data about analysts updates
Screeners with GNCA included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Genocea Biosciences doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
FAQ
- What is the primary business of Genocea Biosciences?
- What is the ticker symbol for Genocea Biosciences?
- Does Genocea Biosciences pay dividends?
- What sector is Genocea Biosciences in?
- What industry is Genocea Biosciences in?
- What country is Genocea Biosciences based in?
- When did Genocea Biosciences go public?
- Is Genocea Biosciences in the S&P 500?
- Is Genocea Biosciences in the NASDAQ 100?
- Is Genocea Biosciences in the Dow Jones?
- When was Genocea Biosciences's last earnings report?
- When does Genocea Biosciences report earnings?
What is the primary business of Genocea Biosciences?
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy using neoantigen-targeted peripheral cells for ATLAS identified anti-tumor antigens that are used to manufacture peripheral blood-derived tumor-specific T cell therapy; and GEN-009, a neoantigen vaccine candidate, delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts.
What is the ticker symbol for Genocea Biosciences?
The ticker symbol for Genocea Biosciences is NASDAQ:GNCA
Does Genocea Biosciences pay dividends?
No, Genocea Biosciences does not pay dividends
What sector is Genocea Biosciences in?
Genocea Biosciences is in the Healthcare sector
What industry is Genocea Biosciences in?
Genocea Biosciences is in the Biotechnology industry
What country is Genocea Biosciences based in?
Genocea Biosciences is headquartered in United States
When did Genocea Biosciences go public?
Genocea Biosciences's initial public offering (IPO) was on 05 February 2014
Is Genocea Biosciences in the S&P 500?
No, Genocea Biosciences is not included in the S&P 500 index
Is Genocea Biosciences in the NASDAQ 100?
No, Genocea Biosciences is not included in the NASDAQ 100 index
Is Genocea Biosciences in the Dow Jones?
No, Genocea Biosciences is not included in the Dow Jones index
When was Genocea Biosciences's last earnings report?
Genocea Biosciences's most recent earnings report was on 10 March 2023
When does Genocea Biosciences report earnings?
The date for Genocea Biosciences's next earnings report has not been announced yet